Companies ›Healthcare ›CRVS

CRVS — Nasdaq Pharmaceuticals

Corvus Pharmaceuticals, Inc.

$13,37

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

1,2B USD

P/E

—

EV / Rev

—

Div yield

—

Op margin

—

ROE

-5,7 %

Net margin

—

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$13,99

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Corvus Pharmaceuticals operates as a clinical-stage biopharmaceutical company developing targeted therapies, primarily funded through equity capital markets and supported by strategic licensing agreements.

Business. Corvus Pharmaceuticals, Inc. (CRVS) is a healthcare company operating in the pharmaceuticals industry. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification78 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

Industry groupPharmaceuticals

Generated · model-assisted

Sell-side consensus

BUY7 analysts

7 buy0 hold0 sell

Avg 12m price target33,33

Analyst recommendations

7 analysts · consensus Buy

Buy7

Hold0

Sell0

12-month price target

33,33

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

7 analysts · indicative

Ownership→

Wellington Management Company, LLP

largest disclosed fund holder

Profitability→

-5,7 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning CRVS.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to CRVS. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Corvus Pharmaceuticals, Inc. (CRVS) is a healthcare company operating in the pharmaceuticals industry. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification78 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

Industry groupPharmaceuticals

AI synthesis

GENERATED

Corvus Pharmaceuticals maintains a debt-free capital structure with a debt-to-equity ratio of 0.0 and a robust current ratio of 19.81, indicating strong short-term liquidity coverage. The balance sheet holds $40.1 million in cash and equivalents against total assets of $253.2 million and total liabilities of $12.5 million. The company generated $189.4 million in net proceeds from a follow-on public offering in Q1 2026, which significantly bolstered its equity base to $240.7 million. Despite this liquidity, the company reports negative operating cash flow of -$10.4 million and negative free cash flow of -$10.5 million for the quarter, reflecting ongoing cash burn typical of pre-revenue clinical development stages.

Profitability metrics remain negative, with a net loss of $13.7 million in Q1 2026, resulting in a return on equity of -5.69% and return on assets of -5.41%. The company trades at a price-to-book ratio of 5.23, implying the market assigns significant value to its pipeline potential despite the absence of earnings. Operating income stands at -$14.9 million, driven by research and development expenses and general administrative costs inherent to its clinical-stage operations.

Revenue generation is not yet established from product sales, with the business model relying on capital raises and potential milestone payments from licensing agreements with entities such as Vernalis R&D Limited, Scripps Research Institute, and Monash University. The company operates as a single segment entity, with no disclosed geographic revenue concentration, as its primary activities are focused on domestic research and development.

Growth trajectory is characterized by capital expansion rather than organic revenue growth. The share count increased from 74.7 million at the end of 2025 to 84.1 million in Q1 2026, primarily due to the issuance of 9.1 million shares in the follow-on offering. This capital infusion supports extended runway for clinical trials, but the fundamental growth driver remains the successful progression of its drug candidates through regulatory milestones.

Risk assessment highlights high dilution risk, with the diluted share count of 90.0 million moderately exceeding the basic share count of 84.1 million. Key flags indicate that source documents mention dilution or offering risk, consistent with the company's reliance on equity financing. Liquidity risk is assessed as low due to the substantial cash position relative to liabilities, but the high dilution risk poses a long-term challenge to shareholder value preservation.

Recent events include the completion of a follow-on public offering in January 2026, which was disclosed in an 8-K filing with high severity material items. The company also maintains an At Market offering agreement with Jefferies LLC, providing flexibility for future capital raises. Analyst sentiment remains positive, with a mean recommendation of 1.71 (strong buy) and a mean price target of $33.33, significantly above the current market price of $13.99.

Key takeaways

Strong liquidity position with $40.1M cash and 19.81 current ratio, supported by $189.4M in recent equity proceeds.
High dilution risk flagged due to significant share count increase from follow-on offering and outstanding options/warrants.
Pre-revenue clinical stage with negative profitability metrics (ROE -5.69%, ROA -5.41%) and ongoing cash burn.
Positive analyst sentiment with mean price target of $33.33 vs current price of $13.99, indicating expected upside from pipeline milestones.
Debt-free balance sheet with no interest expense burden, allowing full cash flow allocation to R&D.
Reliance on equity financing for runway, with At Market offering agreement in place for future capital needs.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Quarterly

Annual

QUARTERLYFiled 2026-03-31

Q4 2025 · Quarter highlights

Operating income -$14.9M.

Revenue—

Operating income-$14.9M

Net income-$13.7M

Free cash flow-$10.5M

EPS—

Operating cash flow-$10.4M

Financials

Income statement

Revenue—

Gross profit—

Operating income-$14.9M

Net income-$13.7M

Balance sheet

Total assets$253.2M

Total liabilities$12.5M

Total equity$240.7M

Cash & equivalents$40.1M

Long-term debt—

Cash flow

Operating cash flow-$10.4M

CapEx$91.0k

Free cash flow-$10.5M

SBC$2.6M

Highlights

▍Operating income -$14.9M

Valuation FY

Market price

$13,37

Market cap

$1.26B

Enterprise valueⓘ

$1.22B

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

5.2x

P / Tangible bookⓘ

5.2x

Tangible book

$240.7M

Net cashⓘ

$40.1M

Current ratioⓘ

19.8

Debt / equityⓘ

—

ROAⓘ

-5.4%

ROEⓘ

-5.7%

Cash conversionⓘ

76.0%

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

7.0%

Revenue by segment

Business relationships

Business relationships2 disclosed relationships · 1 type · extracted from filings & disclosures

Subsidiaries2

EX21:b8434c7784fcEX21:b8434c7784fcSubsidiarie97%

EX21:e7831a492365EX21:e7831a492365Subsidiarie97%

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-0,68

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-07-23 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-0,68
Revenue	—no estimate	—no estimate	0 USD
Operating income	—no estimate	—no estimate	-66,9M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution7 analysts

Strong buy2

Buy5

Hold0

Sell0

Strong sell0

12-month price target$33,33 · Median $31,50

Low $27,00High $42,00

Operating income · consensus-66,9M USD

EPS surprise

+72,1 %

reported vs consensus · beat

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$27,00

Mean$33,33

Median$31,50

High$42,00

Spot$13,37

+149.3 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskHigh

Liquidity riskLow

Filing-based flags

Diluted share count is moderately above the basic share count.
Source documents mention dilution or offering risk.

Benchmarks vs cohort

ROE-5,7 %Below median

D/E0,00Above P75

Cash Conv0,76Below median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 1 990 000 sh2 exercises · 11 grants10 insiders

CLARK IAN TDirector · Stock Option (Right to Buy) → Common StockAcquired 15 000 @ $11,60grant · 2026-06-11
Grais LindaDirector · Stock Option (Right to Buy) → Common StockAcquired 15 000 @ $11,60grant · 2026-06-11
Moore David ScottDirector · Stock Option (Right to Buy) → Common StockAcquired 15 000 @ $11,60grant · 2026-06-11
van den Broek RichardDirector · Stock Option (Right to Buy) → Common StockAcquired 15 000 @ $11,60grant · 2026-06-11
Thompson Peter A.Director, 10% owner · Stock Option (Right to Buy) → Common StockAcquired 15 000 @ $11,60grant · 2026-06-11
Chan Andrew C.Director · Stock Option (Right to Buy) → Common StockAcquired 30 000 @ $16,02grant · 2026-04-23
Thompson Peter A.Director, 10% owner · Stock Option (Right to Buy) → Common StockDisposed 30 000 @ $15,00exercise · 2026-01-28
Thompson Peter A.Director, 10% owner · Stock Option (Right to Buy) → Common StockDisposed 15 000 @ $9,70exercise · 2026-01-28
Jones William BentonSee Remarks · Stock Option (Right to Buy) → Common StockAcquired 400 000 @ $8,81grant · 2025-12-04
MILLER RICHARD A MDDirector, President and CEO · Stock Option (Right to Buy) → Common StockAcquired 1 000 000 @ $8,81grant · 2025-12-04
Arcara JeffreyChief Business Officer · Stock Option (Right to Buy) → Common StockAcquired 100 000 @ $8,81grant · 2025-12-04
LEA LEIVChief Financial Officer · Stock Option (Right to Buy) → Common StockAcquired 400 000 @ $8,81grant · 2025-12-04
Moore David ScottDirector · Stock Option (Right to Buy) → Common StockAcquired 30 000 @ $7,04grant · 2025-10-02

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Regulatory filings
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data
Reference data

How metrics are computed

Price To Tangible Book
market_price / (tangible_book_value / shares_outstanding_diluted)
Price To Book
market_price / (adjusted_book_value / shares_outstanding_diluted)
Return On Equity
net_income / total_equity
Enterprise Value
market_cap - net_cash
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Market Price
input from market-data provider (delayed close or quote-shim mid)

Source documents

Corvus Pharmaceuticals, Inc. company facts · 2026-07-23
Corvus Pharmaceuticals, Inc. 10-Q 2026-05-07 · 2026-07-23
Corvus Pharmaceuticals, Inc. 10-K 2026-03-12 · 2026-07-23
Corvus Pharmaceuticals, Inc. 10-Q 2025-11-04 · 2026-07-23
Corvus Pharmaceuticals, Inc. 10-Q 2025-08-07 · 2026-07-23
8-K (sec_8k_material) on CRVS · 2026-07-23
Corvus Pharmaceuticals Inc Market data — analyst estimates · 2026-07-23
Corvus Pharmaceuticals Inc Market data — ESG · 2026-07-23
Corvus Pharmaceuticals, Inc. HA canonical relationships · 2026-07-23

Ownership & reference

Top holders

Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,01 %$34M
T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$23M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$37M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$52M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$25M
Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$2M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$7M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$4M
Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$3M
Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$1M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$30M
Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$3M
MASSACHUSETTS FINANCIAL SERVICES CO /MA/Institutional Investor · as of 2026-03-310,00 %$1M
AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$0M
Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$1M
Invesco QQQ TrustFunds · as of 2026-03-310,00 %$1M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$1M
FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

Insider activity

Net buying3 buys · 0 sellsnet $334K3 insiders · last 365d

Moore David ScottDirector · Common StockBought 21 700 @ $11,53$250K · 2026-06-11
MILLER RICHARD A MDDirector, President and CEO · Common StockBought 1 932 @ $12,01$23K · 2026-05-18
MILLER RICHARD A MDDirector, President and CEO · Common StockBought 5 000 @ $12,05$60K · 2026-05-18
Thompson Peter A.Director, 10% owner · Common StockOther 15 000 @ $2,00$30K · 2026-01-28
Thompson Peter A.Director, 10% owner · Common StockOther 30 000 @ $15,00$450K · 2026-01-28
Thompson Peter A.Director, 10% owner · Common StockOther 15 000 @ $9,70$146K · 2026-01-28
Thompson Peter A.Director, 10% owner · Common StockOther 15 000 @ $12,50$188K · 2026-01-28
Thompson Peter A.Director, 10% owner · Common StockOther 15 000 @ $3,61$54K · 2026-01-28
Thompson Peter A.Director, 10% owner · Common StockOther 15 000 @ $3,27$49K · 2026-01-28
Thompson Peter A.Director, 10% owner · Common StockOther 15 000 @ $2,74$41K · 2026-01-28
Thompson Peter A.Director, 10% owner · Common StockOther 15 000 @ $2,60$39K · 2026-01-28
Thompson Peter A.Director, 10% owner · Common StockOther 15 000 @ $0,99$15K · 2026-01-28
Thompson Peter A.Director, 10% owner · Common StockOther 15 000 @ $0,96$14K · 2026-01-28
Thompson Peter A.Director, 10% owner · Common StockOther 15 000 @ $2,49$37K · 2026-01-28
Thompson Peter A.Director, 10% owner · Common StockOther 15 000 @ $1,64$25K · 2026-01-28
Thompson Peter A.Director, 10% owner · Common StockOther 15 000 @ $2,12$32K · 2026-01-28

Short positioning

18.1Mshares short-4.0% vs prior

12.59days to cover

57.3%short of daily vol

2.6Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

CRVSCanonical

Nasdaq · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskHigh

Liquidity riskLow

Diluted share count is moderately above the basic share count.

Source documents mention dilution or offering risk.

Relationship graph

This companySectorSubsidiaries

Evidence & claims

From filings & derived data

Total operating expenses (annual): USD 42.97MUnknown
Operating income (annual): USD -42.97MUnknown
EPS (diluted) (annual): USD-PER-SHARES -1Unknown
Cash & equivalents (annual): USD 4.58MUnknown
Current liabilities (annual): USD 9.38MUnknown
Current assets (annual): USD 58.21MUnknown
Shares outstanding (annual): 74.7MUnknown
Net income (annual): USD -15.3MUnknown
Shareholders' equity (annual): USD 61.2MUnknown
Total assets (annual): USD 71.12MUnknown
Capex (annual): USD 174KUnknown
Total liabilities (annual): USD 9.91MUnknown
EPS (basic) (annual): USD-PER-SHARES -0Unknown
R&D expense (annual): USD 33.72MUnknown
Operating cash flow (annual): USD -32.8MUnknown
Total assets (annual): USD 68.91MUnknown
Current assets (annual): USD 54.41MUnknown
Total liabilities (annual): USD 36.34MUnknown
Operating cash flow (annual): USD -25.42MUnknown
Net income (annual): USD -62.3MUnknown
Operating income (annual): USD -27.55MUnknown
Shares outstanding (annual): 67.9MUnknown
Total operating expenses (annual): USD 27.55MUnknown
EPS (basic) (annual): USD-PER-SHARES -1Unknown

Showing 24 of 28 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-07-23 04:29 UTCFILINGMaterial 8-K

2026-06-12FILINGFORM 8-K →

2026-06-11 00:00 UTCINSIDER6 insider transactions — 2026-06 · net buy $250k 5 derivative

2026-06-11INSIDERMoore David Scott bought 21.7k sh — Director ~$250k

2026-06-11INSIDERMoore David Scott acquired 15.0k sh Stock Option (Right to Buy) — Director

2026-06-11INSIDERThompson Peter A. acquired 15.0k sh Stock Option (Right to Buy) — Director, 10% owner

2026-06-11INSIDERGrais Linda acquired 15.0k sh Stock Option (Right to Buy) — Director

2026-06-11INSIDERvan den Broek Richard acquired 15.0k sh Stock Option (Right to Buy) — Director

2026-06-11INSIDERCLARK IAN T acquired 15.0k sh Stock Option (Right to Buy) — Director

2026-05-18 00:00 UTCINSIDER2 insider transactions — 2026-05

2026-05-18INSIDERMILLER RICHARD A MD bought 1.9k sh — Director, President and CEO ~$23k

2026-05-18INSIDERMILLER RICHARD A MD bought 5.0k sh — Director, President and CEO ~$60k

2026-05-14FILINGFORM 8-K →

2026-05-07FILING10-Q filing →

2026-05-07FILINGFORM 8-K →

2026-04-24FILINGDEF 14A filing →

2026-04-23 00:00 UTCINSIDER1 insider transaction — 2026-04 1 derivative

2026-04-23FILING8-K filing →

2026-04-23INSIDERChan Andrew C. acquired 30.0k sh Stock Option (Right to Buy) — Director

2026-03-31EARNINGSQuarterly results — Q4 2025 Net USD -13.7M

2026-03-13FILINGFORM 8-K →

2026-03-13FILING424B5 filing →

2026-03-12FILING10-K filing →

2026-03-12FILINGFORM 8-K →

2026-01-28 00:00 UTCINSIDER15 insider transactions — 2026-01 · net buy $1.1M 2 derivative

2026-01-28INSIDERThompson Peter A. transacted 15.0k sh — Director, 10% owner ~$30k

2026-01-28INSIDERThompson Peter A. transacted 30.0k sh — Director, 10% owner ~$450k

2026-01-28INSIDERThompson Peter A. disposed of 15.0k sh Stock Option (Right to Buy) — Director, 10% owner

2026-01-28INSIDERThompson Peter A. disposed of 30.0k sh Stock Option (Right to Buy) — Director, 10% owner

2026-01-23FILINGFORM 8-K →

2026-01-23FILING424B5 filing →

2025-12-31EARNINGSQuarterly results — Q3 2025

2025-12-31EARNINGSAnnual results — FY 2025 Net USD -15.3M

2025-12-04 00:00 UTCINSIDER4 insider transactions — 2025-12 4 derivative

2025-12-04INSIDERMILLER RICHARD A MD acquired 1.00M sh Stock Option (Right to Buy) — Director, President and CEO

2025-12-04INSIDERLEA LEIV acquired 400.0k sh Stock Option (Right to Buy) — Chief Financial Officer

2025-12-04INSIDERJones William Benton acquired 400.0k sh Stock Option (Right to Buy) — See Remarks

2025-12-04INSIDERArcara Jeffrey acquired 100.0k sh Stock Option (Right to Buy) — Chief Business Officer

2025-10-02 00:00 UTCINSIDER1 insider transaction — 2025-10 1 derivative

Showing the 40 most recent of 47 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread